Patients’ Characteristics
| . | IFN + PUVA . | IFN + Acitretin . |
|---|---|---|
| Randomized patients | 49 | 49 |
| Evaluable patients | 40 | 42 |
| Sex | ||
| Male | 25 (62.5) | 37 (88.1)* |
| Female | 15 (37.5) | 5 (11.9) |
| Age (yr) | ||
| Median | 58.8 | 58.4 |
| Range | 30-81 | 26-82 |
| Pretreatment | ||
| No | 16 (40.0) | 8 (19.0) |
| Yes | 24 (60.0) | 34 (81.0)† |
| Skin involvement | ||
| T1 | 17 (42.5) | 20 (47.6) |
| T2 | 18 (45.0) | 19 (45.3) |
| T3 | 5 (12.5) | 3 (7.1) |
| Lymph node involvement | ||
| N0,1 | 40 (100.0) | 41 (97.6) |
| N2,3 | 0 | 1 (2.4) |
| Stage of disease | ||
| Ia | 17 (42.5) | 19 (45.2) |
| Ib | 14 (35.0) | 14 (33.3) |
| IIa | 4 (10.0) | 6 (14.3) |
| IIb | 5 (12.5) | 3 (7.2) |
| . | IFN + PUVA . | IFN + Acitretin . |
|---|---|---|
| Randomized patients | 49 | 49 |
| Evaluable patients | 40 | 42 |
| Sex | ||
| Male | 25 (62.5) | 37 (88.1)* |
| Female | 15 (37.5) | 5 (11.9) |
| Age (yr) | ||
| Median | 58.8 | 58.4 |
| Range | 30-81 | 26-82 |
| Pretreatment | ||
| No | 16 (40.0) | 8 (19.0) |
| Yes | 24 (60.0) | 34 (81.0)† |
| Skin involvement | ||
| T1 | 17 (42.5) | 20 (47.6) |
| T2 | 18 (45.0) | 19 (45.3) |
| T3 | 5 (12.5) | 3 (7.1) |
| Lymph node involvement | ||
| N0,1 | 40 (100.0) | 41 (97.6) |
| N2,3 | 0 | 1 (2.4) |
| Stage of disease | ||
| Ia | 17 (42.5) | 19 (45.2) |
| Ib | 14 (35.0) | 14 (33.3) |
| IIa | 4 (10.0) | 6 (14.3) |
| IIb | 5 (12.5) | 3 (7.2) |